FDA Clears Advanced Test for Monitoring Metastatic Colorec...(neSearch(TM) assays that use molecular t...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
Date:11/20/2007
neSearch(TM) assays that use molecular technology to diagnose, stage and more accurately characterize tumors. http://www.veridex.com
'/>"/>
| SOURCE Veridex, LLC Copyright©2007 PR Newswire. All rights reserved |
Related medicine technology :
1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
(Date:12/17/2009)... RALEIGH, N.C., Dec. 17 Pharmaceutical Institute ... from GeneEd, Inc., a company specializing in life ... advanced e-courses, help expand Pharmaceutical Institute,s already extensive ... Institute is a leading provider of specialized training ... a subsidiary of Campbell Alliance. Financial terms ...
(Date:12/17/2009)... PHOENIX, Dec. 17 The Make-A-Wish Foundation ... million donation from the LATISSE ® ... sponsored by Allergan, Inc. ,, Based on the ... a wish come true, the campaign launched earlier ... the Make-A-Wish Foundation by leveraging the excitement around ...
(Date:12/16/2009)... Cell Therapeutics, Inc. (CTI) (Nasdaq ... February 10, 2010 the U.S. Food and ... will review the New Drug Application (NDA) ... aggressive non-Hodgkin,s lymphoma (NHL). ODAC is an ... concerning the efficacy and safety of marketed ...
Breaking Medicine Technology:Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 2Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 3The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 2The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 3The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 4The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 5Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4Cambrex Reports Second Quarter 2009 Results 53671 1Cambrex Reports Second Quarter 2009 Results 53671 2Cambrex Reports Second Quarter 2009 Results 53671 3Cambrex Reports Second Quarter 2009 Results 53671 4Cambrex Reports Second Quarter 2009 Results 53671 5Cambrex Reports Second Quarter 2009 Results 53671 6Cambrex Reports Second Quarter 2009 Results 53671 7Cambrex Reports Second Quarter 2009 Results 53671 8Cambrex Reports Second Quarter 2009 Results 53671 9Cambrex Reports Second Quarter 2009 Results 53671 10Cambrex Reports Second Quarter 2009 Results 53671 11Cambrex Reports Second Quarter 2009 Results 53671 12Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11 2009 53666 1Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 1Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 2Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 3Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 4Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 5Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 6Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 7Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 8Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 9Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 10[0] Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc.[0] The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign[0] Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
... at least 45% additional,reduction in patients' LDL-cholesterol ... May 17, 2007 /PRNewswire-FirstCall/ -- Isis,Pharmaceuticals, Inc. ... clinical trial of ISIS 301012 in patients ... which were,presented in March at the of ...
... 17, 2007 - BioLineRx Ltd. (TASE:,BLRX), Israel's ... containing data from its successfully completed,phase I ... GABA-enhanced,antipsychotic for the treatment of schizophrenia, have ... scientific,conferences. The data will be presented at ...
Other Medicine Technology:Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 2BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 3(Date:12/17/2009)... Helped, Healed, and Preserved Good Health , ... ... Association (IHRSA) announced today that as part of its Campaign for ... abilities to make 2010 the year we unite in a national ... daily exercise is highly valued and widely practiced. IHRSA is inviting ...
(Date:12/17/2009)... , , THURSDAY, Dec. 17 (HealthDay News) -- Among teenage ... least one of three common sexually transmitted infections -- ... becoming sexually active, a new study has found. , ... also found that it was common for these patients ... within four to six months after treatment of the ...
(Date:12/17/2009)... of Science in Human Resource Development Degree Online , ... ... -- Open enrollment has begun for Villanova’s newly online ... professionals whose busy schedules can’t accommodate a campus-based program. With ... online in March 2010, location is no longer a barrier ...
(Date:12/17/2009)... SAN DIEGO, Dec. 17 Neurocrine Biosciences, Inc. ... entered into a privately negotiated transaction to sell an ... to affiliates of Venrock at a price of $2.09 ... approximately $10 million. Neurocrine expects the financing to close ... closing conditions. ,, A shelf registration statement ...
(Date:12/17/2009)... Procedure Provides Efficient Mechanism to Pursue Approval ... Dec. 17 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... it has initiated the regulatory approval process ... under the Decentralized Procedure (DCP). The DCP ... company to simultaneously pursue regulatory approval for ...
Breaking Medicine News(10 mins):Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 2Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 3Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 4Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 5Health News:STDs Common Among Sexually Active Teen Girls in Cities 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 2Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 3Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 2Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 3[0] IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active [0] STDs Common Among Sexually Active Teen Girls in Cities[0] A World-Class HR Master's Degree Is Now Within Reach – 100% Online [0] Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million[0] Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe
... aspiring nurses about careers and online education. , ... ... the recent launch of their new website, online nursing degree ... their goal of connecting students with schools, Online Nursing Career also ...
... (Nasdaq: JAZZ ) announced today that the company ... November 11, 2008 at 2:50 p.m. EST, Dr. Samuel ... at the,Rodman & Renshaw 10th Annual Healthcare Conference in ... at 3:30 p.m. MST (5:30 p.m. EST), Dr.,Saks will ...
... of Zyvox and Cubicin is Driven Strongly ... a New Report from AMR and Decision,Resources, ... 4 Arlington,Medical Resources (AMR) and Decision Resources ... infections caused by methicillin-resistant Staphylococcus,aureus (MRSA), an ...
... Be Sold by A Uniquely-Trained Sales ... ... PSK) today announced that SANCUSO(R) (Granisetron Transdermal System),is now available by prescription ... was approved by,the U.S. Food and Drug Administration (F.D.A.) in September 2008 ...
... /PRNewswire-FirstCall/ Medizone International,Inc. (Pink Sheets: MZEI) announces ... TDV Global, Inc. (TDVGlobal.com). TDV Global,is a ... Approximately 70% of their business involves consulting ... private enterprise,mostly in the Health and Security ...
... rates far below goals, study finds , , TUESDAY, Nov. ... asthma and other high-risk illnesses are getting flu shots, ... from 1992 to 2002 for 18,703 adolescents with asthma, ... During the study period, vaccination rates improved, but only ...
Other Medicine News:Health News:Online Nursing Degree Seekers Gain a New Education Resource: OnlineNursingCareer.com 2Health News:Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections 2Health News:Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections 3Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3Health News:Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc. 2Health News:Too Many High-Risk Teens Not Getting Flu Shots 2Online Nursing Degree Seekers Gain a New Education Resource: OnlineNursingCareer.com Jazz Pharmaceuticals to Present at Investor ConferencesActivity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure InfectionsSANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now AvailableMedizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc.Too Many High-Risk Teens Not Getting Flu Shots
Modular Specimen Filing System has five cells that can hold either slides or tissue cassettes....
Shandon Microscope Slide Cabinet with Drawers...
... is the first solid-state,photocoagulator to ... wavelengths. This advanced,laser system makes ... a red or green wavelength,during ... and ensures effective,patient results., For ...
... The PSL utilizes a high luminance white LED ... lightweight, compact design, to give you the freedom ... The PSL Slit Lamp weighs only about 1.5 ... easily and comfortably in your hand. Its ...
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |